Prognostic significance of Tks5 expression in gliomas

Journal of Clinical Neuroscience

Volumn 19, Issue 3, 2012, Pages 436-442

  Stylli, Stanley S ^a   Stacey, T T I ^b   Kaye, Andrew H ^a   Lock, Peter ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

Cortactin; Glioma; Invadopodia; Prognosis; Tks5

Indexed keywords

ACTIN; ADAPTOR PROTEIN; CORTACTIN; INVADOPODIA PROTEIN; PROTEIN TYROSINE KINASE; TKS5 ADAPTOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CELL; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER PROGNOSIS; DISEASE ASSOCIATION; DISEASE SPECIFIC SURVIVAL; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ADULT; AGED; ASTROCYTOMA; BLOTTING, WESTERN; BRAIN NEOPLASMS; CORTACTIN; FEMALE; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SRC HOMOLOGY DOMAINS; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84856762203     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2011.11.013     Document Type: Article

References (47)

1. A. Jemal, M.M. Center, and C. DeSantis Global patterns of cancer incidence and mortality rates and trends Cancer Epidemiol Biomarkers Prev 19 2010 1893 1907
2. P. Kleihues, and L.H. Sobin World Health Organization classification of tumors Cancer 88 2000 2887
3. B.K. Edwards, M.L. Brown, and P.A. Wingo Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment J Natl Cancer Inst 97 2005 1407 1427
4. J.F. de Groot, K.R. Lamborn, and S.M. Chang Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study J Clin Oncol 29 2011 2689 2695
5. F.M. Iwamoto, K.R. Lamborn, and J.G. Kuhn A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03 Neuro Oncol 13 2011 509 516
6. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
7. S. Bao, Q. Wu, and R.E. McLendon Glioma stem cells promote radioresistance by preferential activation of the DNA damage response Nature 444 2006 756 760
8. A. Giese, and M. Westphal Treatment of malignant glioma: a problem beyond the margins of resection J Cancer Res Clin Oncol 127 2001 217 225
9. M.D. Prados, W.K. Yung, and P.Y. Wen Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American Brain Tumor Consortium study Cancer Chemother Pharmacol 61 2008 1059 1067
10. D.B. Hoelzinger, T. Demuth, and M.E. Berens Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment J Natl Cancer Inst 99 2007 1583 1593
11. R. Buccione, G. Caldieri, and I. Ayala Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix Cancer Metastasis Rev 28 2009 137 149
12. A.M. Weaver Invadopodia Curr Biol 18 2008 R362 R364
13. S.S. Stylli, A.H. Kaye, and P. Lock Invadopodia: at the cutting edge of tumour invasion J Clin Neurosci 15 2008 725 737
14. S. Linder, C. Wiesner, and M. Himmel Degrading devices: invadosomes in proteolytic cell invasion Annu Rev Cell Dev Biol 2010
15. Y.Y. Chuang, N.L. Tran, and N. Rusk Role of synaptojanin 2 in glioma cell migration and invasion Cancer Res 64 2004 8271 8275
16. D.A. Murphy, and S.A. Courtneidge The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function Nat Rev Mol Cell Biol 12 2011 413 426
17. P. Lock, C.L. Abram, and T. Gibson A new method for isolating tyrosine kinase substrates used to identify fish, an SH3 and PX domain-containing protein, and Src substrate Embo J 17 1998 4346 4357
18. C.L. Abram, D.F. Seals, and I. Pass The adaptor protein fish associates with members of the ADAMs family and localizes to podosomes of Src-transformed cells J Biol Chem 278 2003 16844 16851
19. D.F. Seals, E.F. Azucena Jr., and I. Pass The adaptor protein Tks5/Fish is required for podosome formation and function, and for the protease-driven invasion of cancer cells Cancer Cell 7 2005 155 165
20. M. Oser, H. Yamaguchi, and C.C. Mader Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation J Cell Biol 186 2009 571 587
21. B. Blouw, D.F. Seals, and I. Pass A role for the podosome/invadopodia scaffold protein Tks5 in tumor growth in vivo Eur J Cell Biol 87 2008 555 567
22. T. Oikawa, T. Itoh, and T. Takenawa Sequential signals toward podosome formation in NIH-src cells J Cell Biol 182 2008 157 169
23. S.S. Stylli, T.T. Stacey, and A.M. Verhagen Nck adaptor proteins link Tks5 to invadopodia actin regulation and ECM degradation J Cell Sci 122 2009 2727 2740
24. H. Yamaguchi, M. Lorenz, and S. Kempiak Molecular mechanisms of invadopodium formation: the role of the N-WASP-Arp2/3 complex pathway and cofilin J Cell Biol 168 2005 441 452
25. M. Baldassarre, A. Pompeo, and G. Beznoussenko Dynamin participates in focal extracellular matrix degradation by invasive cells Mol Biol Cell 14 2003 1074 1084
26. D.A. Murphy, B. Diaz, and P.A. Bromann A Src-Tks5 pathway is required for neural crest cell migration during embryonic development PLoS ONE 6 2011 e22499
27. M.A. Eckert, T.M. Lwin, and A.T. Chang Twist1-induced invadopodia formation promotes tumor metastasis Cancer Cell 19 2011 372 386
28. V.V. Artym, Y. Zhang, and F. Seillier-Moiseiwitsch Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function Cancer Res 66 2006 3034 3043
29. E.S. Clark, A.S. Whigham, and W.G. Yarbrough Cortactin is an essential regulator of matrix metalloproteinase secretion and extracellular matrix degradation in invadopodia Cancer Res 67 2007 4227 4235
30. M. Oser, C.C. Mader, and H. Gil-Henn Specific tyrosine phosphorylation sites on cortactin regulate Nck1-dependent actin polymerization in invadopodia J Cell Sci 123 2010 3662 3673
31. S.M. Sheen-Chen, C.Y. Huang, and Y.Y. Liu Cortactin in breast cancer: analysis with tissue microarray Anticancer Res 31 2011 293 297
32. X.Z. Xu, M.V. Garcia, and T.Y. Li Cytoskeleton alterations in melanoma: aberrant expression of cortactin, an actin-binding adapter protein, correlates with melanocytic tumor progression Mod Pathol 23 2010 187 196
33. J.H. Gibcus, M.F. Mastik, and L. Menkema Cortactin expression predicts poor survival in laryngeal carcinoma Br J Cancer 98 2008 950 955
34. P. Hofman, C. Butori, and K. Havet Prognostic significance of cortactin levels in head and neck squamous cell carcinoma: comparison with epidermal growth factor receptor status Br J Cancer 98 2008 956 964
35. H.K. Gan, A.H. Kaye, and R.B. Luwor The EGFRvIII variant in glioblastoma multiforme J Clin Neurosci 16 2009 748 754
36. N. Shinojima, K. Tada, and S. Shiraishi Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme Cancer Res 63 2003 6962 6970
37. K. Watanabe, O. Tachibana, and K. Sata Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas Brain Pathol 6 1996 217 223 discussion 23-4
38. S.S. Stylli, M. Howes, and L. MacGregor Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome J Clin Neurosci 11 2004 584 596
39. S.S. Stylli, and A.H. Kaye Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies J Clin Neurosci 13 2006 709 717
40. S.S. Stylli, A.H. Kaye, and L. MacGregor Photodynamic therapy of high grade glioma - long term survival J Clin Neurosci 12 2005 389 398
41. B.Z. Yuan, X. Zhou, and D.B. Zimonjic Amplification and overexpression of the EMS 1 oncogene, a possible prognostic marker, in human hepatocellular carcinoma J Mol Diagn 5 2003 48 53
42. M.L. Luo, X.M. Shen, and Y. Zhang Amplification and overexpression of CTTN (EMS1) contribute to the metastasis of esophageal squamous cell carcinoma by promoting cell migration and anoikis resistance Cancer Res 66 2006 11690 11699
43. J.H. Chen, K.Y. Chen, and H.I. Ma Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma Chin J Physiol 53 2010 234 244
44. T. Matsuo, Y. Miyata, and S. Watanabe Pathologic significance and prognostic value of phosphorylated cortactin expression in patients with sarcomatoid renal cell carcinoma Urology 78 2011 476e9 476e15
45. D.K. Lynch, S.C. Winata, and R.J. Lyons A Cortactin-CD2-associated protein (CD2AP) complex provides a novel link between epidermal growth factor receptor endocytosis and the actin cytoskeleton J Biol Chem 278 2003 21805 21813
46. K.B. Hotary, E.D. Allen, and P.C. Brooks Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix Cell 114 2003 33 45
47. R. Bernards, and R.A. Weinberg A progression puzzle Nature 418 2002 823